Microbix to Present at Key Diagnostic Conference
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF), a leader in life sciences innovation, is all set to attend and exhibit at the prestigious Association for Diagnostic & Laboratory Medicine (ADLM) conference. Scheduled for late July, this event gathers key professionals from the diagnostic and laboratory industries and is a prime opportunity for Microbix to highlight its advancements in diagnostics.
Showcasing Leading Solutions in Diagnostics
During the ADLM event, Microbix will showcase an extensive portfolio of quality assessment products, known as QAPs™. These products are designed to bolster the accuracy of diagnostic tests, particularly antigen and molecular tests, which are crucial for the effective treatment of infectious diseases. Microbix's presence at the conference will not only enable it to exhibit its latest innovations but also foster discussions with existing and potential clients regarding enhancing their quality management systems.
Presenting Groundbreaking Research
In addition to showcasing products, Microbix will present findings from a pioneering External Quality Assessment (EQA) program that utilizes its QAPs. A key poster presentation titled "Quality Control Rapid Response in Pre-Pandemic Preparedness Showcasing a Synthetic H5N1 Genetic Template" will review the efficacy of new QAPs in detecting pre-existing molecular test capabilities against emerging pandemic strains like H5N1 (Bird Flu). This research reveals insights into how current technology can adapt to potential future threats.
Significance of H5N1 in Public Health
Microbix's work with H5N1 is particularly timely given the strain's severe implications for public health. With its pandemic potential, H5N1 has demonstrated devastating impacts, being lethal to nearly 50% of those infected. The company's collaboration with American Proficiency Institute (API) emphasizes the urgency and relevance of this research in ensuring adequate preparation and response for future health crises.
Expert Insights and Capabilities
Amer Alagic, Microbix's Director of R&D and lead author on the poster, emphasized the importance of accurate diagnostic tests for H5N1. He noted, "Our team is privileged to collaborate with API to address critical questions about the effectiveness of flu tests in detecting H5N1. Our novel QAPs are designed to provide full genomic coverage of potential pandemic strains and are manufactured using cutting-edge synthetic biology techniques." These QAPs are meticulously characterized, accurately quantified, and are available in liquid formats and FLOQSwabs to facilitate various testing scenarios.
Catering to Global Diagnostics
Microbix is committed to driving global health through its products, which are now available in over 30 countries. The company caters to a wide range of clients in the diagnostics industry, from test developers to clinical labs and accreditation organizations. With an ISO 9001 & 13485 accreditation, Microbix ensures that its products meet the highest quality standards necessary for safe and effective diagnostics.
About Microbix Biosystems Inc.
As a frontrunner in creating proprietary biological products for human health, Microbix has an impressive workforce of over 120 employees, with a monthly revenue target of C$ 2 million or more. The company is well-regarded for its development of essential ingredients for diagnostic assays, notably including antigens used in immunoassays and its quality assessment products that support lab proficiency testing.
Get in Touch
For inquiries about purchasing QAPs or other products from Microbix, interested parties are encouraged to reach out directly.
Contact Information:
Cameron Groome, CEO
(905) 361-8910
Jim Currie, CFO
(905) 361-8910
Deborah Honig, Investor Relations
Phone: (647) 203-8793
Email: customer.service@microbix.com
Frequently Asked Questions
What is Microbix Biosystems known for?
Microbix Biosystems specializes in the creation of proprietary biological products that enhance diagnostic test accuracy and reliability.
What products will Microbix showcase at ADLM?
Microbix will showcase its quality assessment products, QAPs™, which ensure the accuracy of various diagnostic tests.
Why is H5N1 significant to Microbix's research?
The H5N1 strain poses a serious health threat due to its high mortality rate and potential for pandemic spread.
How can I contact Microbix for inquiries?
Contact Microbix via phone at (905) 361-8910 or through email at customer.service@microbix.com.
Where does Microbix operate?
Microbix operates globally, with its products available in over 30 countries, contributing significantly to the diagnostics industry.
